Francis Medical, Inc., a Minneapolis, MN-based medical machine firm, raised $80M in Collection C fairness funding.
The spherical was led by Arboretum Ventures and Solas BioVentures with participation from Orlando Well being Ventures and two further strategic companions, together with earlier buyers Coloplast A/S and Tonkawa.
Led by CEO and President Michael Kujak, Francis Medical is dedicated to growing urological most cancers therapies which are robust on most cancers and mild on sufferers, with a compassionate perception that minimally invasive therapies can successfully deal with cancerous tissue.
The corporate intends to make use of the funds to speed up the VAPOR 2 pivotal scientific research for the administration of prostate most cancers and the event and U.S. commercialization of its Vanquish Water Vapor Ablation proprietary prostate most cancers remedy, anticipated by the top of 2025.
The VAPOR 2 research is a potential, multicenter, single-arm research that’s evaluating the protection and efficacy of the Vanquish Water Vapor Ablation System for prostate most cancers. Knowledge gathered from the VAPOR 2 research will help 510(okay) clearance, which Francis expects to file for in July 2025. Beforehand, the corporate was awarded FDA Breakthrough Machine standing for Vanquish on the energy of its VAPOR 1 Early Feasibility Research, printed within the Journal of Endocrinology in November 2022. The VAPOR 1 research reported no critical opposed occasions, no device-related opposed occasions, and no unanticipated opposed machine results as its main endpoint. In 87% of sufferers handled, six-month biopsy outcomes indicated no remaining Gleason Grade Group 2 or higher clinically important illness within the focused remedy areas.
FinSMEs
07/01/2025
